No­var­tis' CDK4/6 med Kisqali, firm­ly the sales un­der­dog against Pfiz­er's Ibrance, drops big OS da­ta

With block­buster Ibrance from Pfiz­er in its sights, No­var­tis push­ing hard to build the clin­i­cal case for CDK4/6 in­hibitor Kisqali with three years on the mar­ket. In terms of over­all sur­vival, Kisqali just dropped a ma­jor win in spe­cif­ic breast can­cer pa­tients, and it could help the drug bridge the sales gap.

Adding No­var­tis’ CDK4/6 in­hibitor Kisqali to en­docrine ther­a­py gave pre­menopausal HR-pos­i­tive, HER2-neg­a­tive breast can­cer pa­tients a me­di­an of 11 ex­tra months to live over en­docrine ther­a­py alone, mark­ing a 24% death risk re­duc­tion, ac­cord­ing to Phase III da­ta from the Monaleesa-7 tri­al un­veiled Wednes­day at the vir­tu­al San An­to­nio Breast Can­cer Sym­po­sium.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.